Analyst Reco. Eli Lilly and Company

Equities

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 01:30:02 11/04/2026 am IST			5-day change	1st Jan Change
939.47 ^USD	-1.65%		+0.42%	-12.58%

10/04	Wall Street Gets a CPI Lifeline
10/04	LifeMD Now Offers Eli Lilly's Foundayo to Eligible Patients Through its Weight Management Program	MT

Analyst Reco.

10/04	Rothschild & Co Redburn Adjusts Price Target on Eli Lilly to $880 From $875, Maintains Neutral Rating	MT
09/04	Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says	MT
02/04	Eli Lilly's Foundayo Seen as Preferred Obesity Pill on Ease of Use, BofA Says	MT
02/04	BofA Securities Raises Price Target on Eli Lilly to $1,294 From $1,293, Maintains Buy Rating	MT
31/03	Analyst recommendations: Berkshire Hathaway, Blackrock, Eli Lilly, Unilever, Toyota…
30/03	Guggenheim Adjusts Price Target on Eli Lilly to $1,163 From $1,168, Maintains Buy Rating	MT
18/03	Health Care Down After HSBC Cuts Lilly Rating - Health Care Roundup	DJ
17/03	Analyst recommendations: Align Technology, Eli Lilly, Adobe, Salesforce…
17/03	HSBC Downgrades Eli Lilly to Reduce From Hold, Adjusts Price Target to $850 From $1,070	MT
12/03	Novo Nordisk Price Target Cut as Berenberg Expects Lower CagriSema Sales Amid Recent Clinical Data	MT
11/03	Wolfe Research Adjusts PT on Eli Lilly to $1,325 From $1,250, Maintains Outperform Rating	MT
09/03	Global markets live: Live Nation, Eli Lilly, Amazon, Microsoft, ABB…
26/02	Biogen Faces Uncertain Outlook for Alzheimer's Drug But Pipeline Supports Growth, RBC Says	MT
26/02	Guggenheim Adjusts Price Target on Eli Lilly to $1,168 From $1,161, Maintains Buy Rating	MT
25/02	Eli Lilly Set to Benefit From Obesity Franchise Dominance, RBC Says	MT
25/02	RBC Initiates Eli Lilly at Outperform With $1,250 Price Target	MT
25/02	RBC Starts Eli Lilly Coverage at Outperform Amid Expected Obesity Portfolio 'Dominance' Until 2030	MT
23/02	Truist Securities Keeps Eli Lilly at Buy After Head-to-head Trial Results of Novo Nordisk's Obesity Drug	MT
23/02	Abivax Shows Jitters Despite Promising Updates on Obefazimod
23/02	Novo Nordisk Plummets After Setback for Obesity Drug – Shares Hit Lowest Level Since 2021	FW
23/02	Rothschild & Co Redburn Adjusts PT on Eli Lilly to $875 From $830, Maintains Neutral Rating	MT
19/02	Berenberg Ups Estimates, Price Target on Eli Lilly Amid 'Premium Growth, Premium Valuation'	MT
19/02	Berenberg Adjusts Price Target on Eli Lilly to $1,050 From $950, Maintains Hold Rating	MT
18/02	Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) used together delivered superior efficacy in first-of-its-kind phase 3b trial	RE
18/02	Daiwa Securities Adjusts Price Target on Eli Lilly to $1,250 From $1,230, Maintains Buy Rating	MT